Brief: HLS Therapeutics reports Q2 results
11/08/2022 11:47
Aug 11 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q2 FISCAL 2022 FINANCIAL
RESULTS
* Q2 2022 REVENUE OF $15.5 MILLION
* Q2 2022 NET LOSS WAS $0.28
* Q2 EARNINGS PER SHARE VIEW $-0.08, REVENUE VIEW $16.6
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nCNWL3NlXa
Further company coverage: HLS.TO
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease